Fusion Antibodies PLC
FAB
Company Profile
Business description
Fusion Antibodies PLC offers various antibody engineering services for all therapeutic and diagnostic antibody development stages. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.
Contact
1 Springbank Road
Springbank Industrial Estate, Dunmurry
BelfastBT17 0QL
GBRT: +44 2890432800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
18
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.60 | 15.10 | 0.17% |
| CAC 40 | 7,923.52 | 27.58 | 0.35% |
| DAX 40 | 23,977.72 | 97.00 | 0.41% |
| Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
| FTSE 100 | 9,416.06 | 65.63 | 0.70% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,660.01 | 68.86 | 0.30% |
| Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
| NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
| S&P 500 | 6,688.46 | 27.25 | 0.41% |
| S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |